New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
15:37 EDTUNM, EQR, GILD, XOOM, BWLD, ULTI, AXS, EW, CHRW, AMP, HI, ATO, JKHY, CVD, MAC, CERN, AFL, GIMO, DV, HAIN, DATA, GNWNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Gilead Sciences (GILD), consensus 50c; AFLAC (AFL), consensus $1.39; Ameriprise Financial (AMP), consensus $1.81; Equity Residential (EQR), consensus 69c; Cerner (CERN), consensus 39c; CH Robinson Worldwide (CHRW), consensus 68c; Unum Group (UNM), consensus 84c; Macerich (MAC), consensus 92c; Edwards Lifesciences (EW), consensus 71c; Genworth Financial (GNW), consensus 30c; Covance (CVD), consensus 84c; AXIS Capital (AXS), consensus $1.47; Tableau Software (DATA), consensus 0c; Jack Henry & Associates (JKHY), consensus 60c; Ultimate Software (ULTI), consensus 41c; Hain Celestial (HAIN), consensus 87c; Atmos Energy (ATO), consensus 86c; Buffalo Wild Wings (BWLD), consensus $1.07; DeVry (DV), consensus 73c; Hillenbrand (HI), consensus 52c; Xoom (XOOM), consensus (1c); Gigamon (GIMO), consensus 12c.
News For GILD;AFL;AMP;EQR;CERN;CHRW;UNM;MAC;EW;GNW;CVD;AXS;DATA;JKHY;ULTI;HAIN;ATO;BWLD;DV;HI;XOOM;GIMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 8, 2015
10:01 EDTEQROn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:03 EDTCERN, DATACerner, Tableau announce collaboration
Cerner Corp. (CERN) has collaborated with Tableau Software (DATA) to enhance the data discovery experience of health care organizations through interactive data exploration. The integration of Tableau's visual analytics with Cerner's HealtheAnalytics and HealtheEDW enterprise data warehouse and analytic offerings enables health care organizations to manipulate data and make new discoveries. Through this data mining and analysis, health care organizations can derive meaningful insight to identify trends, improve clinical decision support and help enable continuous improvement.
06:52 EDTEQREquity Residential initiated with an Outperform at BMO Capital
Subscribe for More Information
06:21 EDTAMPAmeriprise assumed with an Outperform at Keefe Bruyette
Subscribe for More Information
05:48 EDTMACStocks with implied volatility movement; MAC RIG
Subscribe for More Information
April 7, 2015
17:58 EDTGILDGilead submits NDA for investigational combination for treatment of HIV-1
Subscribe for More Information
16:00 EDTGILDOptions Update; April 7, 2015
Subscribe for More Information
11:09 EDTMACOptions with decreasing implied volatility
Subscribe for More Information
10:05 EDTCERNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:34 EDTCERNCerner, Allscripts not pricing in DoD contract win, says Deutsche Bank
Subscribe for More Information
April 6, 2015
16:19 EDTCERNCerner initiated with a Hold at Stifel
15:02 EDTDVDeVry announces new credit agreement with up to $550M potential capacity
Subscribe for More Information
13:36 EDTHAINHain Celestial price target raised to $74 from $70 at Argus
Subscribe for More Information
11:11 EDTMACOptions with decreasing implied volatility
Options with decreasing implied volatility: BDSI CONN HLSS CTRX DANG ARCP KMX MAC
09:05 EDTCERNBarclays healthcare distribution analysts hold analyst/industry conference call
Subscribe for More Information
08:31 EDTGNWGenworth sale of Life and Annuity business would be positive, says UBS
UBS said the reported potential sale of Genworth's Life and Annuity insurance company would be done at a discount, but the unit should attract potential buyers. The firm sees its sale as positive, given the unit's lack of near-term free cash flow and low ratings. UBS continues to see long-term value in Genworth, citing its debt reduction and growing cash position, and reiterated its Buy rating and $11 price target on the shares.
07:36 EDTGILDGilead Q1 HCV revenue poised to beat expectations, says RBC Capital
After analyzing weekly prescription data, RBC Capital believes that Gilead's weekly hepatitis C prescriptions are tracking towards $3.5B-$3.6B of revenue from hepatitis C drugs for Q1, versus the consensus outlook of about $2.6B. The firm keeps an Outperform rating on Gilead.
06:59 EDTMACMacerich reinstated with a Neutral at JPMorgan
Subscribe for More Information
06:00 EDTMACStocks with implied volatility movement; MAC AIG
Stocks with implied volatility movement; Macerich (MAC) 27, AIG (AIG) 20 according to iVolatility.
April 5, 2015
14:43 EDTGILDActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use